PolyPid said it has entered a key regulatory transition for D-PLEX100, with its rolling NDA submission to the FDA underway and the remaining clinical module expected to be filed imminently. The ...

Structural imaging based on magnetic resonance is an integral part of the clinical assessment of patients with suspected Alzheimer dementia. Prospective data on the natural history of change in ...

In the clinic, tumour dormancy is observed in local recurrences or metastases. It usually refers to the time after treatment that a patient is asymptomatic but still carries local remnant or ...

Image source: The Motley Fool. PolyPid (NASDAQ:PYPD) is nearing completion of its rolling NDA for D-PLEX100, with imminent clinical module submission poised to trigger the FDA review process. The ...

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate ...

Chief Operating Officer, U.S. Warshavsky stated that recent SHIELD II data, showing a "64% relative risk reduction with a P value of 0.0103 in severe wound events," directly aligns with hospital and ...

Sangamo Therapeutics Inc (SGMO) has made progress in the rolling submission of the BLA for ST920 in Fabry disease, with the first two modules submitted. The FDA has reaffirmed that an additional ...

Ocugen missed EPS expectations, reporting a loss of $0.06 per share. Revenue significantly surpassed forecasts, with a surprise of over 205%. Stock price declined sharply by 21.35% post-earnings ...

$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds ...

Greetings, and welcome to PolyPid's First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for today's ...

Good afternoon, and welcome to Sangamo Therapeutics First Quarter 2026 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to ...

Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $0.01. Operator: Good afternoon, and welcome to Sangamo Therapeutics First Quarter 2026 ...